Receptors, Leukotriene B4
"Receptors, Leukotriene B4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cell surface leukotriene receptors with a preference for leukotriene B4. Leukotriene B4 receptor activation influences chemotaxis, chemokinesis, adherence, enzyme release, oxidative bursts, and degranulation in polymorphonuclear leukocytes. There are at least two subtypes of these receptors. Some actions are mediated through the inositol phosphate and diacylglycerol second messenger systems.
|Receptors, Leukotriene B4
- Receptors, Leukotriene B4
- Leukotriene B4 Receptors
- LTB4 Receptors
- Receptors, LTB4
- LTB4 Receptor
- Receptor, LTB4
- Leukotriene B4 Receptor
- Receptor, Leukotriene B4
Below are MeSH descriptors whose meaning is more general than "Receptors, Leukotriene B4".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Leukotriene B4".
This graph shows the total number of publications written about "Receptors, Leukotriene B4" by people in this website by year, and whether "Receptors, Leukotriene B4" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Leukotriene B4" by people in Profiles.
Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. Anticancer Drugs. 2007 Jun; 18(5):535-41.
Ding XZ, Talamonti MS, Bell RH, Adrian TE. A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs. 2005 Jun; 16(5):467-73.